ArticleTobacco prevention & cessation2026
Patient and healthcare system factors associated with participation in municipal smoking cessation programs after hospitalization for atherosclerotic vascular disease in Norway: A prespecified analysis of two randomized controlled trials.
Article in Tobacco prevention & cessation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Persistent smoking after hospitalization for an atherosclerotic vascular event remains common, and only a small proportion attend cardiac rehabilitation or community-based lifestyle support, including smoking cessation programs. This study aimed to identify patient and healthcare system factors associated with participation in a municipal smoking cessation program among patients with atherosclerotic vascular disease included in a smoking cessation trial. Methods: A prespecified secondary analysis was conducted of two randomized cessation trials with patients recruited between 2021 and 2023 at three hospitals in Norway. Hospitalized patients with established atherosclerotic vascular disease who smoked at least one cigarette daily were randomized to motivational counseling with proactive referral to the municipal cessation program (intervention) or brief advice and contact information (control). Data were collected from medical records and self-report questionnaires. Associations between patient and healthcare system factors and program participation were explored using logistic regression analyses, adjusting for age, site and group allocation. Results: In all, 268 of 280 patients were eligible at 6 months (median age 65 years, 39% women). Participation in the cessation program was 42% (56/134) in the intervention and 9% (12/134) in the control group. Among participants, 57% (39/68) quit smoking, compared with 30% (59/200) among non-participants. In the total sample, older age (adjusted odds ratio, AOR=0.65 per 10 year increase; 95% CI: 0.47-0.90), living alone versus with others (AOR=0.30; 95% CI: 0.14-0.65), and lower versus higher education (AOR=0.40; 95% CI: 0.18-0.89) were negatively associated with participation. Analysis restricted to the intervention group yielded consistent findings. Conclusions: Participation in a municipal smoking cessation program among hospitalized patients with atherosclerotic vascular disease remained suboptimal, despite proactive motivational counseling and proactive referral. Older patients, those living alone, and patients with lower level of education were less likely to participate, highlighting the need for targeted referral strategies and tailored support for these groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.